Nektar Therapeutics Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Howard W. Robin; PEO total compensation $6.26M; PEO compensation actually paid $14.14M; Other NEO average total compensation $1.22M.
- 2024-12-31: PEO Howard W. Robin; PEO total compensation $3.76M; PEO compensation actually paid $5.35M; Other NEO average total compensation $1.12M.
- 2023-12-31: PEO Howard W. Robin; PEO total compensation $3.14M; PEO compensation actually paid -$773.20K; Other NEO average total compensation $1.12M.
- 2022-12-31: PEO Howard W. Robin; PEO total compensation $11.28M; PEO compensation actually paid -$8.74M; Other NEO average total compensation $3.09M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Howard W. Robin | $6.26M | $14.14M | $1.22M | $1.92M | $16.58 | $124.75 | -$164.00M | 2026-04-24 | |
| 2024-12-31 | Howard W. Robin | $3.76M | $5.35M | $1.12M | $1.43M | $5.47 | $93.49 | -$119.00M | 2026-04-24 | |
| 2023-12-31 | Howard W. Robin | $3.14M | -$773.20K | $1.12M | -$2.64K | $3.32 | $94.03 | -$276.00M | 2026-04-24 | |
| 2022-12-31 | Howard W. Robin | $11.28M | -$8.74M | $3.09M | -$3.43M | $13.29 | $89.90 | -$368.00M | 2026-04-24 | |
| 2021-12-31 | Howard W. Robin | $11.15M | $8.03M | $4.38M | $3.29M | $79.47 | $100.02 | -$524.00M | 2026-04-24 | |
| 2024-12-31 | Howard Robin | $3.76M | $5.35M | $1.12M | $1.43M | $4.31 | $118.20 | -$119.00M | 2025-04-25 | |
| 2023-12-31 | Howard Robin | $3.14M | -$773.20K | $1.12M | -$2.64K | $2.62 | $118.87 | -$276.00M | 2025-04-25 | |
| 2022-12-31 | Howard Robin | $11.28M | -$8.74M | $3.09M | -$3.43M | $10.47 | $113.65 | -$368.00M | 2025-04-25 | |
| 2021-12-31 | Howard Robin | $11.15M | $8.03M | $4.38M | $3.29M | $62.59 | $126.45 | -$524.00M | 2025-04-25 | |
| 2020-12-31 | Howard Robin | $11.24M | $6.46M | $4.38M | $2.02M | $78.76 | $126.42 | -$444.00M | 2025-04-25 | |
| 2023-12-31 | Howard W. Robin | $3.14M | -$773.20K | $1.12M | -$2.64K | $2.62 | $118.87 | -$276.00M | Relative TSR (Percentile Rank) $7.00 | 2024-04-26 |
| 2022-12-31 | Howard W. Robin | $11.28M | -$8.74M | $3.09M | -$3.43M | $10.47 | $113.65 | -$368.00M | $9.00 | 2024-04-26 |
| 2021-12-31 | Howard W. Robin | $11.15M | $8.03M | $4.38M | $3.29M | $62.59 | $126.45 | -$524.00M | $52.00 | 2024-04-26 |
| 2020-12-31 | Howard W. Robin | $11.24M | $6.46M | $4.38M | $2.02M | $78.76 | $126.42 | -$444.00M | $30.00 | 2024-04-26 |
| 2022-12-31 | Howard W. Robin | $11.28M | -$8.74M | $3.09M | -$3.43M | $10.47 | $113.65 | -$368.00M | Relative TSR Percentile $9.00 | 2023-04-28 |
| 2021-12-31 | Howard W. Robin | $11.15M | $8.03M | $4.38M | $3.29M | $62.59 | $126.45 | -$524.00M | $52.00 | 2023-04-28 |
| 2020-12-31 | Howard W. Robin | $11.24M | $6.46M | $4.38M | $2.02M | $78.76 | $126.42 | -$444.00M | $30.00 | 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |